Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive double-blind placebo-controlled trial of treatments for adults with COVID-19 pneumonia
2020-001367-88Phase 3Terminated
- Sponsor
- Department of Infectious Diseases
- Start
- Apr 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydroxychloroquine, baricitinib, sarilumab and COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Department of Infectious Diseases. Primary endpoint: Primary composite endpoint. Started Apr 2020; status: terminated.
02
Drugs
hydroxychloroquinebaricitinibsarilumabCOVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001367-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001367-88.